The Authority

The Authority

The Authority

Flow Forward Closes $1.3 Million of Additional Series A Financing

Human Health published May 18, 2015


Flow Forward Medical Inc. today announced that it has closed a $1.3 million round of additional Series A financing, led by existing investor, the Kansas Bioscience Authority (KBA).

Read More | Share This

Traverse Biosciences Executes Agreement with Aratana for Periodontal Disease in Dogs and Cats

Animal Health published May 04, 2015


Traverse Biosciences announced that it has executed a $250,000 cooperative research and development agreement (CRADA) with Aratana Therapeutics Inc. (NASDAQ:PETX) to advance the development of TRB-N0224 for the treatment and control of periodontal disease in companion animals, including dogs and cats.

Read More | Share This

AAD announces three new board members

Animal Health published March 26, 2015


KBA's Tony Simpson joins top agricultural and life science executives to support emerging era of animal agriculture –
rapid, on-farm diagnostics for early disease detection

Read More | Share This

Metactive Closes $2 Million of Additional Series A Financing

Human Health published February 23, 2015


Metactive Medical Inc. today announced that it has closed on $2 million of additional Series A financing, led by the Kansas Bioscience Authority (KBA), an existing Metactive investor.

Read More | Share This

Kansas Bioscience Authority to dramatically increase available funds

General published January 29, 2015


By Alyssa Scott, KU Statehouse Wire Service

Read More | Share This

Advanced Animal Diagnostics Closes $15 Million in Oversubscribed Series C Funding

Animal Health published December 08, 2014


New investors join in support of diagnostic solutions that benefit the food supply

Read More | Share This

Aratana licenses treatment for dogs with atopic dermatitis

Animal Health published October 13, 2014


Aratana Therapeutics Inc. has finalized a global licensing agreement with Ukraine-based Atopix Therapeutics Ltd. to develop and commercialize a drug for dogs to treat atopic dermatitis, also known as eczema.

Read More | Share This

InvestMidwest starts application process for entrepreneurs

General published October 02, 2014


The InvestMidwest Venture Capital Forum is accepting applications from entrepreneurs with high-growth companies ho

Read More | Share This

Biova LLC announces new, second location in Kansas Bioscience Park

Human Health published September 24, 2014


Johnston, Iowa, USA—Biova LLC, the world leader for water soluble egg membrane ingredients, has expanded their cutting-edge technology into a new neighborhood.The new Biova office at 10900 S.Clay

Read More | Share This

Aratana seeks more than $40M in latest public stock offering

Animal Health published September 17, 2014


Aratana Therapeutics Inc. announced Wednesday it will offer 4.5 million shares of its common stock at $9.25 a share, which would raise abou

Read More | Share This

CritiTech Names Mechanical Systems, Inc. As Its Exclusive Drug Manufacturing Equipment Supplier

General published August 26, 2014


LAWRENCE, KS – CritiTech, Inc. has named Mechanical Systems, Inc. (MSI) of Wichita, Kan., as its official and exclusive supplier of fine-particle drug manufacturing equipment.

Read More | Share This

KC Animal Health Corridor Grows to Represent 56 Percent of Global Industry Sales

Animal Health published August 25, 2014


August 25, 2014 – The Kansas City Animal Health Corridor has released new evidence of the global impact of the KC region’s animal health industry concentration. Companies with a strategic location in the KC Animal Health Corridor now represent 56 percent of total worldwide animal health, diagnostics and pet food sales.

Read More | Share This

FlexiLume Dental LED System Receives FDA Approval

Human Health published August 18, 2014


Mission, Kansas -  EMCI is proud to announce that the FlexiLume Dental LED System has received regulatory clearance for sale worldwide, including FDA approval and CE mark.Peter Lucas, COO of EMCI,

Read More | Share This

HEARTLAND PLANT INNOVATIONS HIRES NEW CHIEF SCIENTIST

Agribusiness published August 12, 2014


Heartland Plant Innovations (HPI) has announced the hiring of Dr. Muhammad Asif as its new Chief Scientist. Asif will be charged with leading HPI’s scientific efforts including novel trait development as well as the Advanced Plant Breeding Services. HPI offers wheat doubled haploids, wide hybridization/trait introgression, and genotyping as services to customers world-wide. All services are provided without claim to intellectual property which makes HPI attractive to wheat breeders working on advanced germplasm.

Read More | Share This

Aratana Therapeutics Reports Second Quarter 2014 Results

Animal Health published August 12, 2014


Aratana Therapeutics, Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals, today announced its second quarter 2014 results.

Read More | Share This

CritiTech and European Medical Contract Manufacturing Announce Collaboration

Human Health published August 05, 2014


LAWRENCE, KS – CritiTech, Inc., a growing drug delivery and development company, announced today that it has entered into a collaboration with European Medical Contract Manufacturing (EMCM) of Nijmegen, Netherlands, to develop tissue grafts coated with a variety of drugs using CritiTech’s proprietary supercritical fluid technology. The coated tissue grafts are being developed to provide effective and long-lasting antimicrobial control and rapid healing, especially in revision surgeries, to compensate for and correct failed implants.

Read More | Share This

CritiTech Announces Positive Results from Phase I Trial of Nanotax® for Intraperitoneal Cancers

Human Health published June 30, 2014


LAWRENCE, KS – CritiTech, a growing drug delivery and development company, announced today positive results from the Phase I Trial of Nanotax® (“Trial”), a novel fine particle reformulation of paclitaxel to treat intraperitoneal cancers.

Read More | Share This

Metactive Wins First Prize at the Medical Device Entrepreneur's Forum at the ASAIO 60th Annual Conference

Human Health published June 24, 2014


OLATHE, Kan. Metactive Medical, Inc. ("Metactive") announced that it was awarded top prize in a business plan competition hosted by the Medical Device Entrepreneur's Forum, a special session held on June 20, 2014 at the ASAIO 60th Annual Conference in Washington, DC.

Read More | Share This

Aratana Therapeutics Initiates and Doses First Patient in Market Development Studies of AT-005 for Treating Canine T-cell Lymphoma

Animal Health published June 18, 2014


KANSAS CITY, Kan., Aratana Therapeutics, Inc., a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it is currently enrolling patients in two nationwide clinical trials to evaluate its monoclonal antibody for canine T-cell lymphoma, AT-005, which is conditionally licensed by the USDA to aid in the treatment of dogs with lymphoma.

Read More | Share This

IGXBio receives FDA approval to move forward with GenePro® clinical trials

Human Health published June 17, 2014


Lenexa, KS – IGXBio, Inc. has received approval from U.S. Food and Drug Administration (FDA) to begin human clinical trials of GenePro®, a DNA-based HIV vaccine.

Read More | Share This

Aratana Therapeutics licenses new stem cell therapy for arthritis in dogs

Animal Health published June 13, 2014


Aratana Therapeutics Inc.

Read More | Share This

Flow Forward Announces Spinout from Novita

Human Health published May 29, 2014


Flow Forward Medical, Inc., an early-stage medical device company focused on improving outcomes for hemodialysis patients through the rapid creation of high-quality vascular access sites, today an

Read More | Share This

Aratana Therapeutics Reports First Quarter 2014 Results

Animal Health published May 13, 2014


KANSAS CITY, Kan., -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing an

Read More | Share This

Metactive Debuts Novel Embolization Technology

Human Health published March 23, 2014


Metactive Medical, Inc., an early-stage company focused on developing endovascular embolization devices for the treatment of neurovascular and peripheral vascular diseases, today presented new non

Read More | Share This

Terratek® Flex, the Market’s First Compostable Elastomeric Bioplastic

Agribusiness published March 12, 2014


Terratek® Flex, the market’s first compostable elastomeric bioplastic, can be used as an impact modifier for polylactic acid (PLA), increasing impact strength, elongation and flexibility without s

Read More | Share This

Health Outcomes Sciences Completes First Close of Series A Preferred Financing

Human Health published March 05, 2014


Health Outcomes Sciences Inc. (HOS), a leading healthcare IT company based in Overland Park, Kan., today announced that it has completed the first close of its Series A Preferred financing round. The company has raised $5 million in the first closing and expects to raise up to an additional $2 million of capital, bringing the round to $7 million.

Read More | Share This

Metactive Announces Spinout from Novita

Human Health published February 21, 2014


Metactive Medical, Inc., an early-stage company focused on developing embolization devices for the treatment of peripheral vascular and neurovascular diseases, today announced that it has launched

Read More | Share This

Aratana gains conditional approval for cancer drug

Animal Health published January 28, 2014


Aratana Therapeutics Inc.

Read More | Share This

HDL, Inc. Acquires Exclusive U.S. License For Early Lung Cancer Detection Test From Oncimmune Ltd.

Human Health published October 29, 2013


Virginia-based Health Diagnostic Laboratory, Inc. will acquire and operate Oncimmune’s DeSoto, Kansas lab and become the exclusive licensed U.S. provider of EarlyCDT®- Lung, the world’s first autoantibody test for early detection of lung cancer.

Read More | Share This

Aratana Therapeutics is the recipient of KBA Investment

Animal Health published February 06, 2013


OLATHE, Kan. (February 6, 2013) – Aratana Therapeutics is the recipient of a $324,148 investment by the Kansas Bioscience Authority. Previously code-named “Project Gray,” the funding was unanimously approved by the Board of Directors on January 22, 2013. Aratana requested that the details of this investment be kept confidential until the fundraising round closed.

Read More | Share This

Subscribe Via RSS

Upcoming Events

By Sector

Bioenergy Animal Health Human Health Human Health

[ View All Posts ]